MX2022005899A - Moduladores de proteinas basicas de la hepatitis b. - Google Patents
Moduladores de proteinas basicas de la hepatitis b.Info
- Publication number
- MX2022005899A MX2022005899A MX2022005899A MX2022005899A MX2022005899A MX 2022005899 A MX2022005899 A MX 2022005899A MX 2022005899 A MX2022005899 A MX 2022005899A MX 2022005899 A MX2022005899 A MX 2022005899A MX 2022005899 A MX2022005899 A MX 2022005899A
- Authority
- MX
- Mexico
- Prior art keywords
- hepatitis
- core protein
- protein modulators
- modulators
- virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D281/16—[b, f]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D267/20—[b, f]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
La presente invención proporciona, en parte, compuestos que tienen propiedades efectoras alostéricas contra la proteína del núcleo (Cp) del virus de Hepatitis B. También se proporcionan métodos para tratar infecciones virales, tales como hepatitis B, que comprenden administrar, al paciente que necesita del mismo, el compuesto descrito.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562218815P | 2015-09-15 | 2015-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005899A true MX2022005899A (es) | 2022-06-27 |
Family
ID=58289869
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018003198A MX392309B (es) | 2015-09-15 | 2016-09-15 | Moduladores de proteínas básicas de la hepatitis b. |
| MX2018003206A MX2018003206A (es) | 2015-09-15 | 2016-09-15 | Moduladores de la proteína del núcleo de la hepatitis b. |
| MX2018003207A MX2018003207A (es) | 2015-09-15 | 2016-09-15 | Moduladores de proteina del nucleo de hepatitis b. |
| MX2022005899A MX2022005899A (es) | 2015-09-15 | 2018-03-14 | Moduladores de proteinas basicas de la hepatitis b. |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018003198A MX392309B (es) | 2015-09-15 | 2016-09-15 | Moduladores de proteínas básicas de la hepatitis b. |
| MX2018003206A MX2018003206A (es) | 2015-09-15 | 2016-09-15 | Moduladores de la proteína del núcleo de la hepatitis b. |
| MX2018003207A MX2018003207A (es) | 2015-09-15 | 2016-09-15 | Moduladores de proteina del nucleo de hepatitis b. |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US10766890B2 (es) |
| EP (4) | EP3349580B1 (es) |
| JP (4) | JP7023838B2 (es) |
| KR (3) | KR20180053363A (es) |
| CN (4) | CN112094264A (es) |
| AR (3) | AR106040A1 (es) |
| AU (4) | AU2016323293B2 (es) |
| CA (3) | CA2998803A1 (es) |
| CL (2) | CL2018000684A1 (es) |
| CY (1) | CY1123570T1 (es) |
| DK (1) | DK3349580T3 (es) |
| DO (1) | DOP2018000074A (es) |
| EA (3) | EA201890736A1 (es) |
| ES (2) | ES2905950T3 (es) |
| HK (2) | HK1259141A1 (es) |
| HR (1) | HRP20201812T1 (es) |
| HU (1) | HUE051872T2 (es) |
| IL (3) | IL258097A (es) |
| LT (1) | LT3349580T (es) |
| MX (4) | MX392309B (es) |
| MY (1) | MY198974A (es) |
| PH (3) | PH12018500571B1 (es) |
| PT (1) | PT3349580T (es) |
| RS (1) | RS61064B1 (es) |
| SG (1) | SG10202011103UA (es) |
| SI (1) | SI3349580T1 (es) |
| SM (1) | SMT202000630T1 (es) |
| TW (4) | TWI786639B (es) |
| WO (3) | WO2017048954A1 (es) |
| ZA (1) | ZA201802456B (es) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2748029T3 (es) | 2014-03-13 | 2020-03-12 | Univ Indiana Res & Tech Corp | Moduladores alostéricos de proteína núcleo de hepatitis B |
| TWI786639B (zh) | 2015-09-15 | 2022-12-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
| CA3037151A1 (en) * | 2016-09-15 | 2018-03-22 | Assembly Biosciences, Inc. | Hepatitis b core protein modulators |
| US10662416B2 (en) | 2016-10-14 | 2020-05-26 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome |
| SG11201902944TA (en) | 2016-11-07 | 2019-05-30 | Arbutus Biopharma Corp | Substituted pyridinone-containing tricyclic compounds, and methods using same |
| WO2018153285A1 (zh) * | 2017-02-23 | 2018-08-30 | 福建广生堂药业股份有限公司 | 三并环类化合物及其应用 |
| SG11201908012SA (en) | 2017-03-02 | 2019-09-27 | Assembly Biosciences Inc | Cyclic sulfamide compounds and methods of using same |
| AU2018236188B2 (en) * | 2017-03-13 | 2022-01-27 | Assembly Biosciences, Inc. | Process for making hepatitis B core protein modulators |
| CA3056886A1 (en) | 2017-03-21 | 2018-09-27 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same |
| WO2019086142A1 (en) | 2017-11-02 | 2019-05-09 | Aicuris Gmbh & Co. Kg | Novel, highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis b virus (hbv) |
| CN111448199A (zh) | 2017-11-02 | 2020-07-24 | 艾库里斯有限及两合公司 | 具有抗乙型肝炎病毒(hbv)活性的新的高活性的氨基-噻唑取代的吲哚-2-甲酰胺 |
| CN111566120B (zh) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的3’3’环状二核苷酸 |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| CN112334137A (zh) * | 2018-05-03 | 2021-02-05 | 埃默里大学 | 用于nash和其他代谢紊乱的孤儿核受体调节剂 |
| TWI815887B (zh) * | 2018-05-15 | 2023-09-21 | 美商愛彼特生物製藥股份有限公司 | 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法 |
| TWI826492B (zh) | 2018-07-27 | 2023-12-21 | 加拿大商愛彼特生物製藥公司 | 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法 |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| EP3846793B1 (en) | 2018-09-07 | 2024-01-24 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| EP4371987B9 (en) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| KR102658602B1 (ko) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물 |
| AR117188A1 (es) | 2018-11-02 | 2021-07-21 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb) |
| US20220009945A1 (en) | 2018-11-02 | 2022-01-13 | Aicuris Gmbh & Co. Kg | Novel urea 6,7-dihydro-4h-thiazole[5,4-c]pyridines active against the hepatitis b virus (hbv) |
| UY38434A (es) | 2018-11-02 | 2020-05-29 | Aicuris Gmbh & Co Kg | Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv) |
| AR116947A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb) |
| AR116946A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb) |
| AR116948A1 (es) | 2018-11-02 | 2021-06-30 | Aicuris Gmbh & Co Kg | Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (vhb) |
| TWI827760B (zh) | 2018-12-12 | 2024-01-01 | 加拿大商愛彼特生物製藥公司 | 經取代之芳基甲基脲類及雜芳基甲基脲類、其類似物及其使用方法 |
| EP3911413B1 (en) * | 2019-01-17 | 2023-12-06 | F. Hoffmann-La Roche AG | Substituted chromen-4-one for the treatment and prophylaxis of hepatitis b virus infection |
| CN113543851B (zh) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 2’3’-环二核苷酸及其前药 |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| AU2020267015A1 (en) | 2019-04-30 | 2021-12-23 | Aicuris Gmbh & Co. Kg | Novel indole-2-carboxamides active against the hepatitis B virus (HBV) |
| CU20210089A7 (es) | 2019-04-30 | 2022-06-06 | Aicuris Gmbh & Co Kg | Compuestos derivados de fenil y piridil ureas activas contra el virus de la hepatitis b (vhb) |
| WO2020221824A1 (en) | 2019-04-30 | 2020-11-05 | Aicuris Gmbh & Co. Kg | Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv) |
| AU2020266258A1 (en) | 2019-04-30 | 2021-12-23 | Aicuris Gmbh & Co. Kg | Novel oxalyl piperazines active against the hepatitis B virus (HBV) |
| WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| BR112021023622A2 (pt) * | 2019-05-24 | 2022-04-19 | Assembly Biosciences Inc | Composições farmaceuticas para o tratamento de hbv |
| WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CA3149557A1 (en) | 2019-09-30 | 2021-04-08 | Scott J. Balsitis | Hbv vaccines and methods treating hbv |
| EP4063366A4 (en) * | 2019-11-22 | 2023-12-20 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | CRYSTAL FORM OF NUCLEOPROTEIN INHIBITOR AND USE THEREOF |
| WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| TW202146393A (zh) | 2020-03-03 | 2021-12-16 | 美商皮克醫療公司 | Eif4e抑制劑及其用途 |
| EP4118070A4 (en) * | 2020-03-11 | 2024-04-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| CN113929648A (zh) * | 2020-07-14 | 2022-01-14 | 浙江晖石药业有限公司 | 一种环丁烷-1,2-二甲酸酐及其中间体的制备方法 |
| ES3054072T3 (en) | 2020-08-07 | 2026-01-29 | Gilead Sciences Inc | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| JP2024518558A (ja) | 2021-05-13 | 2024-05-01 | ギリアード サイエンシーズ， インコーポレイテッド | ＴＬＲ８調節化合物と抗ＨＢＶ ｓｉＲＮＡ治療薬との組合せ |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| JP2024532276A (ja) | 2021-08-25 | 2024-09-05 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
| US12234231B2 (en) | 2021-08-25 | 2025-02-25 | PIC Therapeutics, Inc. | EIF4E inhibitors and uses thereof |
| CN115521238B (zh) * | 2022-07-02 | 2024-05-31 | 甘肃瀚聚药业有限公司 | 一种n-甲基-2-(2-氯乙基)吡咯烷的制备方法 |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US688762A (en) * | 1901-06-19 | 1901-12-10 | Charles Weber | Toy. |
| GB1480553A (en) | 1976-06-03 | 1977-07-20 | Pfizer Ltd | Tricyclic sulphonamides |
| JPS58225074A (ja) | 1982-06-25 | 1983-12-27 | Chugai Pharmaceut Co Ltd | ジベンゾオキサゼピン誘導体 |
| GB9109557D0 (en) * | 1991-05-02 | 1991-06-26 | Wellcome Found | Chemical compounds |
| US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| DE19624659A1 (de) * | 1996-06-20 | 1998-01-08 | Klinge Co Chem Pharm Fab | Neue Pyridylalken- und Pyridylalkinsäureamide |
| DE102004004928A1 (de) | 2004-01-31 | 2005-08-18 | Bayer Healthcare Ag | Dibenzoxazepine II |
| US20070105819A1 (en) | 2005-10-17 | 2007-05-10 | Roger Olsson | CB-1 modulating compounds and their use |
| WO2007056388A2 (en) * | 2005-11-07 | 2007-05-18 | The General Hospital Corporation | Compositions and methods for modulating poly (adp-ribose) polymerase activity |
| JP4042065B1 (ja) | 2006-03-10 | 2008-02-06 | 健治 吉田 | 情報処理装置への入力処理システム |
| WO2008036139A2 (en) | 2006-06-07 | 2008-03-27 | The Regents Of The University Of California | Inhibitors of mshc and homologs thereof, and methods of identifying same |
| WO2008118141A2 (en) | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| JP2011529053A (ja) | 2008-07-23 | 2011-12-01 | アメリカ合衆国 | 抗マラリア薬としてのプラスモジウム表面アニオンチャンネル阻害剤 |
| RU2586212C2 (ru) * | 2008-12-08 | 2016-06-10 | Мандифарма Интернэшнл Корпорейшн Лимитед | Композиции ингибиторов тирозинкиназных рецепторов белков |
| CN102791687B (zh) * | 2009-12-18 | 2015-02-11 | 北京凯因科技股份有限公司 | C型肝炎病毒复制的新型抑制剂 |
| WO2012045194A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Benzodiazepinones as fak inhibitors for treatment of cancer |
| WO2013006394A1 (en) * | 2011-07-01 | 2013-01-10 | Institute For Hepatitis And Virus Research | Sulfamoylbenzamide derivatives as antiviral agents against hbv infection |
| WO2013010069A1 (en) | 2011-07-13 | 2013-01-17 | Indiana University Research And Technology Corporation | Modified viral structural protein with antiviral activity |
| KR102056665B1 (ko) | 2012-01-06 | 2019-12-17 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 4,4,-이치환-1,4-디하이드로피리미딘 및 b형 간염의 치료를 위한 약제로서 이의 용도 |
| JP2015533782A (ja) | 2012-08-28 | 2015-11-26 | ヤンセン・サイエンシズ・アイルランド・ユーシー | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 |
| ES2610758T3 (es) | 2012-08-28 | 2017-05-03 | Janssen Sciences Ireland Uc | Derivados de sulfamoílo bicíclicos condensados y su uso como medicamentos en el tratamiento de la hepatitis B |
| EP2892893B2 (en) | 2012-09-10 | 2019-10-16 | F.Hoffmann-La Roche Ag | 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
| JP2016502519A (ja) | 2012-11-09 | 2016-01-28 | インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション | Ｈｂｖ集合エフェクターの代替的使用 |
| EP2928459A4 (en) | 2012-12-06 | 2016-10-26 | Baruch S Blumberg Inst | FUNCTIONALIZED BENZAMIDE DERIVATIVES AS ANTIVIRAL ACTIVE AGGREGATORS FOR HBV INFECTIONS |
| HK1217649A1 (zh) | 2012-12-27 | 2017-01-20 | 德雷克塞尔大学 | 針對hbv感染的新型抗病毒劑 |
| RU2519546C1 (ru) | 2013-01-16 | 2014-06-10 | Общество С Ограниченной Ответственностью "Биоинтегратор" (Ооо "Биоинтегратор") | КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16а |
| EP2961732B1 (en) | 2013-02-28 | 2017-04-12 | Janssen Sciences Ireland UC | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
| KR102350704B1 (ko) | 2013-03-15 | 2022-01-13 | 셀젠 카르 엘엘씨 | 헤테로아릴 화합물 및 이의 용도 |
| AU2014247138B2 (en) | 2013-04-03 | 2018-06-28 | Janssen Sciences Ireland Uc | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| JP6533217B2 (ja) | 2013-05-17 | 2019-06-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂ型肝炎ウイルス感染症の治療および予防のための６−架橋ヘテロアリールジヒドロピリミジン類 |
| JO3603B1 (ar) | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي |
| CA2909742C (en) | 2013-05-17 | 2020-08-04 | Janssen Sciences Ireland Uc | Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| EA031077B1 (ru) | 2013-06-19 | 2018-11-30 | Серагон Фармасьютикалз, Инк. | Модулятор рецептора эстрогена и его применения |
| EP3027612B1 (en) * | 2013-07-29 | 2018-10-10 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | 11-oxo-10,11-dihydrodibenzo[b,f][1,4]thiazepine s-oxide derivatives and their use as dopamine d2 receptor antagonists |
| ES2748029T3 (es) | 2014-03-13 | 2020-03-12 | Univ Indiana Res & Tech Corp | Moduladores alostéricos de proteína núcleo de hepatitis B |
| BR112016028934B1 (pt) | 2014-06-10 | 2021-06-22 | Basf Se | Compostos, composição, uso de um composto de fórmula i e método para o combate de fungos fitopatogênicos |
| TWI786639B (zh) | 2015-09-15 | 2022-12-11 | 美商艾森伯利生物科學公司 | B型肝炎核心蛋白質調節劑 |
-
2016
- 2016-09-14 TW TW110118046A patent/TWI786639B/zh not_active IP Right Cessation
- 2016-09-14 TW TW105130076A patent/TW201720802A/zh unknown
- 2016-09-14 TW TW105130078A patent/TWI730985B/zh not_active IP Right Cessation
- 2016-09-14 TW TW105130074A patent/TWI721016B/zh not_active IP Right Cessation
- 2016-09-15 EA EA201890736A patent/EA201890736A1/ru unknown
- 2016-09-15 JP JP2018513782A patent/JP7023838B2/ja not_active Expired - Fee Related
- 2016-09-15 KR KR1020187010455A patent/KR20180053363A/ko not_active Ceased
- 2016-09-15 WO PCT/US2016/051940 patent/WO2017048954A1/en not_active Ceased
- 2016-09-15 US US15/760,387 patent/US10766890B2/en active Active
- 2016-09-15 WO PCT/US2016/051934 patent/WO2017048950A1/en not_active Ceased
- 2016-09-15 ES ES16847305T patent/ES2905950T3/es active Active
- 2016-09-15 CN CN202010540566.9A patent/CN112094264A/zh active Pending
- 2016-09-15 EP EP16847295.9A patent/EP3349580B1/en active Active
- 2016-09-15 HK HK19101106.8A patent/HK1259141A1/zh unknown
- 2016-09-15 AU AU2016323293A patent/AU2016323293B2/en not_active Ceased
- 2016-09-15 HR HRP20201812TT patent/HRP20201812T1/hr unknown
- 2016-09-15 EP EP16847305.6A patent/EP3349581B8/en not_active Not-in-force
- 2016-09-15 PT PT168472959T patent/PT3349580T/pt unknown
- 2016-09-15 CA CA2998803A patent/CA2998803A1/en not_active Abandoned
- 2016-09-15 PH PH1/2018/500571A patent/PH12018500571B1/en unknown
- 2016-09-15 HK HK19101078.2A patent/HK1258697A1/zh unknown
- 2016-09-15 CN CN201680065137.2A patent/CN108348529A/zh active Pending
- 2016-09-15 SI SI201630982T patent/SI3349580T1/sl unknown
- 2016-09-15 MX MX2018003198A patent/MX392309B/es unknown
- 2016-09-15 AR ARP160102819A patent/AR106040A1/es unknown
- 2016-09-15 EP EP20185808.1A patent/EP3782626A1/en not_active Withdrawn
- 2016-09-15 MX MX2018003206A patent/MX2018003206A/es unknown
- 2016-09-15 AR ARP160102820A patent/AR106041A1/es unknown
- 2016-09-15 AU AU2016323305A patent/AU2016323305A1/en not_active Abandoned
- 2016-09-15 KR KR1020187010461A patent/KR20180050405A/ko not_active Withdrawn
- 2016-09-15 EA EA201890731A patent/EA201890731A1/ru unknown
- 2016-09-15 LT LTEP16847295.9T patent/LT3349580T/lt unknown
- 2016-09-15 KR KR1020187010462A patent/KR20180050406A/ko not_active Withdrawn
- 2016-09-15 SG SG10202011103UA patent/SG10202011103UA/en unknown
- 2016-09-15 JP JP2018513837A patent/JP2018531921A/ja active Pending
- 2016-09-15 DK DK16847295.9T patent/DK3349580T3/da active
- 2016-09-15 EA EA201890735A patent/EA201890735A1/ru unknown
- 2016-09-15 HU HUE16847295A patent/HUE051872T2/hu unknown
- 2016-09-15 ES ES16847295T patent/ES2831333T3/es active Active
- 2016-09-15 WO PCT/US2016/051949 patent/WO2017048962A1/en not_active Ceased
- 2016-09-15 MX MX2018003207A patent/MX2018003207A/es unknown
- 2016-09-15 US US15/760,343 patent/US10392379B2/en not_active Expired - Fee Related
- 2016-09-15 AR ARP160102816A patent/AR106037A1/es unknown
- 2016-09-15 SM SM20200630T patent/SMT202000630T1/it unknown
- 2016-09-15 JP JP2018513789A patent/JP2018531919A/ja active Pending
- 2016-09-15 RS RS20201384A patent/RS61064B1/sr unknown
- 2016-09-15 MY MYPI2018000361A patent/MY198974A/en unknown
- 2016-09-15 EP EP16847298.3A patent/EP3349761B1/en not_active Not-in-force
- 2016-09-15 CN CN201680065139.1A patent/CN108347942B/zh not_active Expired - Fee Related
- 2016-09-15 AU AU2016323297A patent/AU2016323297A1/en not_active Abandoned
- 2016-09-15 US US15/760,284 patent/US10377748B2/en active Active
- 2016-09-15 CA CA2998741A patent/CA2998741C/en active Active
- 2016-09-15 CN CN201680065785.8A patent/CN108347943B/zh not_active Expired - Fee Related
- 2016-09-15 CA CA2998793A patent/CA2998793A1/en not_active Abandoned
-
2018
- 2018-03-13 IL IL258097A patent/IL258097A/en unknown
- 2018-03-13 IL IL258099A patent/IL258099A/en unknown
- 2018-03-14 IL IL258124A patent/IL258124B/en active IP Right Grant
- 2018-03-14 MX MX2022005899A patent/MX2022005899A/es unknown
- 2018-03-15 PH PH12018500573A patent/PH12018500573A1/en unknown
- 2018-03-15 DO DO2018000074A patent/DOP2018000074A/es unknown
- 2018-03-15 CL CL2018000684A patent/CL2018000684A1/es unknown
- 2018-03-15 PH PH12018500572A patent/PH12018500572A1/en unknown
- 2018-04-13 ZA ZA2018/02456A patent/ZA201802456B/en unknown
-
2019
- 2019-05-28 CL CL2019001433A patent/CL2019001433A1/es unknown
- 2019-05-30 US US16/426,727 patent/US10968211B2/en not_active Expired - Fee Related
-
2020
- 2020-11-16 CY CY20201101088T patent/CY1123570T1/el unknown
-
2021
- 2021-01-04 US US17/140,800 patent/US11814376B2/en active Active
- 2021-01-18 JP JP2021005706A patent/JP7150903B2/ja active Active
- 2021-04-01 AU AU2021202065A patent/AU2021202065B2/en not_active Ceased
-
2023
- 2023-09-01 US US18/460,337 patent/US20240025890A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500573A1 (en) | Hepatitis b core protein modulators | |
| MX2019003525A (es) | Moduladores alostericos de proteina nucleo de hepatitis b. | |
| NZ730809A (en) | Methods for treating filoviridae virus infections | |
| EA201791515A1 (ru) | Соединения пиразина для лечения инфекционных заболеваний | |
| EA201691726A1 (ru) | Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b | |
| EA026667B9 (ru) | Фармацевтическая композиция для лечения вируса гепатита с | |
| PH12017550022A1 (en) | Phosphoramidates for the treatment of hepatitis b virus | |
| NZ631726A (en) | Therapeutic compounds for the treatment of viral infections | |
| JOP20180008A1 (ar) | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b | |
| BR112018009009A2 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
| MX2017000312A (es) | Derivados de isoindolina para usarse en el tratamiento de una infeccion viral. | |
| BR112017026061A2 (pt) | composto, uso de um composto, e, método de tratamento de uma infecção viral | |
| PH12014500385A1 (en) | Benzofuran compounds for the treatment of hepatitis c virus infections | |
| EA201890818A1 (ru) | Режим комбинированной терапии для лечения hcv | |
| EA201500942A1 (ru) | ПРОТИВОВИРУСНЫЙ ИНДОЛО[2,3-b]ХИНОКСАЛИН | |
| EA201590297A1 (ru) | Гетероциклические карбоксамиды для лечения вирусных заболеваний | |
| PH12017500816A1 (en) | Long acting pharmaceutical compositions for hepatitis c | |
| EA201691835A1 (ru) | Аллостерические модуляторы капсидного белка гепатита в | |
| BR112016020895A2 (pt) | moduladores alostéricos da proteína do núcleo da hepatite b | |
| HK40005971A (en) | Phosphoramidates for the treatment of hepatitis b virus | |
| BR112017013188A2 (pt) | processo para preparar compostos semelhantes à oxatiazina |